公开(公告)号：US20220105207A1

公开(公告)日：2022-04-07

申请号：US17552984

申请日：2021-12-16

Applicant: Wisconsin Alumni Research Foundation

Inventor： Jamey Weichert ,  Reinier Hernandez ,  Ray Zhang ,  Anatoly Pinchuk

IPC: A61K51/04 ,  A61K9/00 ,  A61B5/055 ,  C07B59/00 ,  A61K49/00 ,  C07F9/6524 ,  A61K49/10 ,  A61K49/08

Abstract: Dual-modality contrast agents are disclosed herein, having the general formula: R1 includes a chelating moiety that is chelated to a Mn2+ isotope. The disclosed contrast agents differentially target a wide range of malignant tumor tissues, and can be simultaneously used as contrast agents for both magnetic resonance imaging (MRI) and positron emission topography (PET) imaging. Accordingly, the disclosed contrast agent can be used in diagnosing and monitoring solid tumor cancers.

公开(公告)号：US20200237935A1

公开(公告)日：2020-07-30

申请号：US16851585

申请日：2020-04-17

Applicant: Wisconsin Alumni Research Foundation

Inventor： Jamey Weichert ,  Reinier Hernandez ,  Ray Zhang ,  Anatoly Pinchuk

IPC: A61K51/04 ,  A61K9/00 ,  A61B5/055 ,  C07B59/00 ,  A61K49/00 ,  C07F9/6524 ,  A61K49/10 ,  A61K49/08

Abstract: Dual-modality contrast agents are disclosed herein, having the general formula: R1 includes a chelating moiety that is chelated to a Mn2+ isotope. The disclosed contrast agents differentially target a wide range of malignant tumor tissues, and can be simultaneously used as contrast agents for both magnetic resonance imaging (MRI) and positron emission topography (PET) imaging. Accordingly, the disclosed contrast agent can be used in diagnosing and monitoring solid tumor cancers.

公开(公告)号：US20190184040A1

公开(公告)日：2019-06-20

申请号：US16222364

申请日：2018-12-17

Applicant: Wisconsin Alumni Research Foundation

Inventor： Jamey Weichert ,  Reinier Hernandez ,  Ray Zhang ,  Anatoly Pinchuk

IPC: A61K51/04 ,  C07B59/00 ,  A61B5/055 ,  A61K9/00

CPC classification number: A61K51/0474 ,  A61B5/055 ,  A61K9/0019 ,  C07B59/002

Abstract: Dual-modality contrast agents are disclosed herein, having the general formula: R1 includes a chelating moiety that is chelated to a Mn2+ isotope. The disclosed contrast agents differentially target a wide range of malignant tumor tissues, and can be simultaneously used as contrast agents for both magnetic resonance imaging (MRI) and positron emission topography (PET) imaging. Accordingly, the disclosed contrast agent can be used in diagnosing and monitoring solid tumor cancers.